• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Strive (ASST) Rebounds Hard But Is The Valuation Already Too Rich

    Simply Wall St·10/02/2026 00:33:09
    語音播報

    Strive (ASST) has drawn fresh attention after its recent trading performance. The stock closed at US$30.11 and has shown sharp moves over the past month that contrast with its weaker one year total return.

    The recent 30-day share price return of 25.46% and 90-day share price return of 129.67% suggest that momentum in Strive is building again, even though the one-year total shareholder return declined 43.40%, which leaves longer-term holders still under water.

    Capitalize on the renewed momentum in Strive by comparing it with a hand picked set of 27 high quality undervalued stocks that also pair strong fundamentals with recent price strength.

    Strive has shifted from substantial one-year losses to a rapid short-term rebound, which raises a simple issue for anyone eyeing the stock now: does the current price still leave enough potential upside to justify the risk?

    Preferred Price-to-Book of 4x for Strive: Is it justified?

    Strive’s rebound comes with a valuation tag that matters. On a P/B of 4x at a last close of $30.11, the stock sits well above the broader US Medical Equipment sector, which trades on an average P/B of 2.5x, so the market is clearly paying a higher price relative to book value than for the typical peer.

    The price to book ratio compares the share price with the company’s net assets per share. For an asset manager like Strive that is still loss making, P/B often becomes a key reference point because earnings based measures are less useful when net income is currently a loss of $975.46m and return on equity is negative.

    That premium does not come with much fundamental comfort. Strive is unprofitable today, is forecast to remain loss making over the next 3 years, and carries a negative return on equity, while its revenue outlook of 10.9% a year is described as slower than both the wider US market and the 20% high growth threshold. Against that backdrop, a 4x P/B signals that investors are paying up despite the absence of near term profitability.

    Relative to the sector, the gap is clear. The US Medical Equipment industry average P/B is 2.5x, and Strive’s 4x multiple is described as expensive against that yardstick, even though it is portrayed as good value versus a narrower peer group where the average P/B is 7.9x. That split points to a stock that is priced richer than the typical industry player, but cheaper than some closer comparables that trade on much higher book value multiples.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 4x (OVERVALUED)

    Still, the sharp one-year total return decline of 43.40% and the current losses of $975.456m could quickly reset sentiment if momentum cools.

    Find out about the key risks to this Strive narrative.

    Next Steps

    Does this mix of short-term strength and longer-term damage leave you confident or cautious on Strive right now? If you want to move quickly but still base your view on more than headline moves, it is worth weighing both the bright spots and the weak links using the 1 key reward and 3 important warning signs.

    Looking for more investment ideas beyond Strive?

    If Strive has your attention but you want a broader watchlist, use the Simply Wall St Screener to quickly surface fresh ideas that match your style.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.